TY - JOUR
T1 - A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk
AU - Travis, Ruth C
AU - Appleby, Paul N.
AU - Martin, Richard M
AU - Holly, Jeff M.P.
AU - Albanes, Demetrius
AU - Black, Amanda
AU - Bueno de Mesquita, H Bas
AU - Chan, June M.
AU - Chen, Chu-Chih
AU - Chirlaque, Maria-Dolores
AU - Cook, Michael B.
AU - Deschasaux, Mélanie
AU - Donovan, Jenny L.
AU - Ferrucci, Luigi
AU - Galan, Pilar
AU - Giles, Graham G.
AU - Giovannucci, Edward L.
AU - Gunter, Marc J.
AU - Habel, Laurel A.
AU - Hamdy, Freddie C
AU - Helzlsouer, Kathy J.
AU - Hercberg, Serge
AU - Hoover, Robert N
AU - Janssen, Joseph A.M.J.L.
AU - Kaaks, Rudolf J
AU - Kubo, Tatsuhiko
AU - Le Marchand, Loic
AU - Metter, E. Jeffrey
AU - Mikami, Kazuya
AU - Morris, Joan K.
AU - Neal, David E.
AU - Neuhouser, Marian L.
AU - Ozasa, Kotaro
AU - Palli, Domenico
AU - Platz, Elizabeth A.
AU - Pollak, Michael N.
AU - Price, Alison J.
AU - Roobol, Monique J.
AU - Schaefer, Catherine
AU - Schenk, Jeannette M.
AU - Severi, Gianluca
AU - Stampfer, Meir Jonathan
AU - Stattin, Pär
AU - Tamakoshi, Akiko
AU - Tangen, Catherine M.
AU - Touvier, Mathilde
AU - Wald, Nicholas J.
AU - Weiss, Noel S.
AU - Ziegler, Regina G
AU - Key, Timothy J
AU - Allen, Naomi E.
AU - on behalf of the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
PY - 2016/4/15
Y1 - 2016/4/15
N2 - The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.
AB - The role of insulin-like growth factors (IGF) in prostate cancer development is not fully understood. To investigate the association between circulating concentrations of IGFs (IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3) and prostate cancer risk, we pooled individual participant data from17 prospective and two cross-sectional studies, including up to 10,554 prostate cancer cases and 13,618 control participants. Conditional logistic regression was used to estimate the ORs for prostate cancer based on the study-specific fifth of each analyte. Overall, IGF-I, IGF-II, IGFBP-2, and IGFBP-3 concentrations were positively associated with prostate cancer risk (Ptrend all ≤ 0.005), and IGFBP-1 was inversely associated weakly with risk (Ptrend = 0.05). However, heterogeneity between the prospective and cross-sectional studies was evident (Pheterogeneity = 0.03), unless the analyses were restricted to prospective studies (with the exception of IGF-II, Pheterogeneity = 0.02). For prospective studies, the OR for men in the highest versus the lowest fifth of each analyte was 1.29 (95% confidence interval, 1.16-1.43) for IGF-I, 0.81 (0.68-0.96) for IGFBP-1, and 1.25 (1.12-1.40) for IGFBP-3. These associations did not differ significantly by time-to-diagnosis or tumor stage or grade. Aftermutual adjustment for each of the other analytes, only IGF-I remained associated with risk. Our collaborative study represents the largest pooled analysis of the relationship between prostate cancer risk and circulating concentrations of IGF-I, providing strong evidence that IGF-I is highly likely to be involved in prostate cancer development. Cancer Res; 76(8); 2288-300.
UR - http://www.scopus.com/inward/record.url?scp=84969972281&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-15-1551
DO - 10.1158/0008-5472.CAN-15-1551
M3 - Article
C2 - 26921328
AN - SCOPUS:84969972281
SN - 0008-5472
VL - 76
SP - 2288
EP - 2300
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -
